Skip to content
  • Patients
  • Contact
  • Patients
  • Contact
KaliVir Immunotherapeutics
  • Our Company
  • Our Science
  • Pipeline
  • STEALTH-001 Trial
  • Careers
  • News
  • Our Company
  • Our Science
  • Pipeline
  • STEALTH-001 Trial
  • Careers
  • News

Category: In the news

How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies

This site contains information about VET3-TGI, an investigational agent that has not been reviewed or approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy have not been established.

KaliVir Immunotherapeutics

KaliVir Immunotherapeutics, Inc.
240 Alpha Drive
Pittsburgh, PA 15238
412-435-6730

Research & Innovation

  • Our Science
  • VET™ Platform
  • Discovery Research
  • Pipeline
  • STEALTH-001 Study
  • Publications
  • Presentations
  • Our Science
  • VET™ Platform
  • Discovery Research
  • Pipeline
  • STEALTH-001 Study
  • Publications
  • Presentations

Company

  • About Us
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Partnering
  • Careers
  • About Us
  • Leadership
  • Board of Directors
  • Advisory Boards
  • Partnering
  • Careers

Resources

  • News
  • Contact
  • News
  • Contact

Forward-looking statements

This website contains forward-looking statements within the meaning of applicable U.S. securities laws. These statements involve risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied. All statements other than statements of historical fact may be forward-looking, including statements about our plans, strategies and objectives for clinical development, manufacturing and commercialization; our product pipeline and clinical data and their implications; the enforceability of our intellectual property; our competitive position; and the anticipated benefits of our collaborations and partnerships. Information on this website is provided in summary form, speaks only as of the date it was posted, and KaliVir undertakes no obligation to update it except as required by law.

© 2026 KaliVir Immunotherapeutics, Inc. All rights reserved. VET™ is a trademark of KaliVir Immunotherapeutics, Inc.
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Cookie Policy